Weight Watchers Q3 Earnings Preview: Will Ozempic Weigh Down WW Stock?
Portfolio Pulse from Surbhi Jain
WW International Inc (NASDAQ:WW), formerly known as Weight Watchers, is set to report its Q3 earnings on Nov. 2. The company has been struggling with falling revenues and a large debt pile of $1.4 billion. The recent $132 million acquisition of Sequence Health is expected to provide new subscribers access to weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Trulicity. The stock is down about 30% over the past month.
November 02, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
WW International is facing financial struggles with falling revenues and a large debt. The recent acquisition of Sequence Health could potentially boost its revenues, but the stock has been performing poorly, down 30% over the past month.
The company's financial struggles and large debt are concerning for investors. While the acquisition of Sequence Health could potentially boost revenues, it's uncertain how this will impact the company's financial situation in the short term. The stock's poor performance over the past month also indicates a negative short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Eli Lilly and Co manufactures Mounjaro and Trulicity, two of the weight-loss drugs that WW International's new subscribers will have access to through the Sequence Health acquisition.
While Eli Lilly's weight-loss drugs will be accessible to WW International's new subscribers, it's unclear how this will directly impact Eli Lilly's revenues or stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Novo Nordisk A/S manufactures Ozempic and Wegovy, two of the weight-loss drugs that WW International's new subscribers will have access to through the Sequence Health acquisition.
While Novo Nordisk's weight-loss drugs will be accessible to WW International's new subscribers, it's unclear how this will directly impact Novo Nordisk's revenues or stock price in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50